ClinicalTrials.gg
CompletedNCT04683185Updated Jul 20, 2021

A Study to Assess the Safety and Tolerability of E6742 in Japanese Healthy Adult Participants

A Phase 1 interventional study of E6742 and Placebo in Healthy Volunteers, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-20.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The primary purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending oral doses of E6742 in Japanese healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • E6742
  • Healthy participants
  • Pharmacokinetics
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-smoking, male or female Japanese, greater than or equal to (>=) age 20 years and less than or equal to (\<=) 55 years old at the time of
  2. (BMI) >=18.5 and less than (\<) 25.0 kilogram per meter square (kg/m\^2) at Screening

Exclusion criteria

Exclusion Criteria:

  1. Females who are breastfeeding or pregnant at Screening or Baseline
  2. Females of who:

    • Within 28 days before study entry, did not use a highly effective method of , which includes any of the following:

      • Total abstinence
      • An intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
      • A contraceptive implant
      • An oral contraceptive
      • Have a vasectomized partner with confirmed azoospermia
    • Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation
  3. Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing highly effective contraception throughout the study period and for 5 times the half-life of the study drug plus 90 days after study drug discontinuation)
  4. illness that requires medical treatment within 8 weeks or a clinically significant infection within 4 weeks before dosing
  5. Any history of gastrointestinal surgery that may affect PK profiles of E6742 at Screening
  6. Any clinically abnormal symptom or organ impairment found by medical history, ophthalmic examination or chest X ray test at Screening, or founded by physical examinations, vital signs, finding, or laboratory test results at Screening or Baseline
  7. A prolonged corrected using Fridericia's method (QTcF) interval (QTcF greater than [>] 450 millisecond [ms]) demonstrated on ECG at Screening or Baseline. A history of risk factors for torsade de pointes or the use of concomitant medications that prolonged the QT/QTc interval
  8. Persistent systolic blood pressure >130 millimeter of mercury (mmHg) or diastolic blood pressure >85 mmHg diastolic at Screening or Baseline
  9. Heart rate less than 45 or more than 100 beats per min at Screening or Baseline
  10. Any lifetime history of suicidal ideation or any lifetime history of suicidal behavior as indicated by the Suicidal Ideation section of the Columbia Suicide Severity Rating Scale (C-SSRS)
  11. Any lifetime history of psychiatric disease
  12. Any current psychiatric symptoms as indicated by a standard screening tool (Patient Health Questionnaire 9 [PHQ 9])
  13. Any suicidal ideation with intent with or without a plan within Screening or 6 months before Screening (that is, answering "Yes" to questions 4 or 5 on the C-SSRS)
  14. History of disease or immunodeficiency
  15. Known to be positive for tuberculosis test (T-spot. TB Test) at Screening
  16. Received immunoglobulin or blood preparation within 6 months before the study treatment
  17. Received inoculation within 4 weeks before the study treatment (8 weeks before in case of live or attenuated vaccine)
  18. Family living together or cohabitant of a patient with an influenza virus infection
  19. In contact with Coronavirus disease (COVID 19) patient within 4 weeks before study drug administration
  20. Known to be other than negative for Severe acute respiratory syndrome coronavirus 2 (SARS Cov 2) antibody test at Screening
  21. Known to be other than negative for SARS Cov 2 polymerase chain reaction (PCR) test at Screening or Baseline
  22. History of retinopathy, maculopathy or macular degeneration
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 2: E6742 200 mg or Placebo

    Participants will receive E6742 200 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.

    Drug: E6742 · Drug: Placebo

  • Experimental
    Cohort 3: E6742 400 mg or Placebo

    Participants will receive E6742 400 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.

    Drug: E6742 · Drug: Placebo

  • Experimental
    Cohort 1: E6742 100 milligram (mg) or Placebo

    Participants will receive E6742 100 mg or E6742-matched placebo, tablets, orally, twice daily for 6 days under fasted conditions and once on Day 7 in the morning.

    Drug: E6742 · Drug: Placebo

Interventions

  • DrugE6742

    E6742 tablets.

  • DrugPlacebo

    E6742-matched placebo tablets.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Safety assessments will consist of monitoring and recording all adverse events (AEs) and SAEs; laboratory evaluation for hematology, blood chemistry, and urine values; periodic measurement of vital signs and electrocardiograms (ECGs); and the performance of physical examinations.

    Time frame: Baseline up to 28 days after the last dose of study drug (approximately Day 35)

  2. Cmax: Maximum Observed Plasma Concentration for E6742 and its Metabolite (ER-001132963) on Day 1

    Time frame: Day 1: 0-12 hours

  3. tmax: Time at Which the Highest Drug Plasma Concentration Occurs for E6742 and its Metabolite (ER-001132963) on Day 1

    Time frame: Day 1: 0-12 hours

  4. AUC(0-12h): Area Under the Plasma Concentration-time Curve From Zero Time to 12 Hours Postdose for E6742 and its Metabolite (ER-001132963) on Day 1

    Time frame: Day 1: 0-12 hours

  5. AUC Metabolite to E6742 Ratio Following Molecular Weight Correction to E6742 Equivalents on Day 1

    Time frame: Day 1: 0-12 hours

  6. Css,max: Maximum Observed Plasma Concentration at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  7. tss,max: Time at Which the Highest Drug Plasma Concentration Occurs at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  8. Css,av: Average Steady State Plasma Concentration for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  9. AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  10. AUC(0-12hr): Area Under the Plasma Concentration-time Curve Within a Dosing Interval at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-12 hours

  11. t1/2: Terminal Elimination Phase Half-life for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  12. CLss/F: Apparent Total Clearance at Steady State for E6742 on Day 7

    Time frame: Day 7: 0-168 hours

  13. Vss/F: Apparent Volume of Distribution at Steady State for E6742 on Day 7

    Time frame: Day 7: 0-168 hours

  14. PTF: Peak-trough Fluctuation for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  15. Accumulation Ratio for Cmax and AUC for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-168 hours

  16. Metabolite to E6742 AUC Ratio Following Molecular Weight Correction to E6742 Equivalents on Day 7

    Time frame: Day 7: 0-168 hours

  17. AUC(0-12hr)ss: Area Under the Plasma Concentration-time Curve Within a Dosing Interval at Steady State for E6742 and its Metabolite (ER-001132963) on Day 7

    Time frame: Day 7: 0-12 hours

Secondary outcomes

  1. Change From Baseline in Corrected QT Interval (QTc) for E6742

    High precision method QT analysis (HPQT) will be performed using data extracted from the 12-hour holter recording obtained from the morning of day 1 (predose) through 12 hours after dosing, the morning of day 7 (predose) through 12 hours after dosing.

    Time frame: Day 1 and 7: 0-12 hours

07

Study locations

1 site
  • Eisai Trial Site #1
    Bunkyō-Ku, Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Jun 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2020
First posted
Dec 24, 2020
StartActual
Dec 28, 2020
Primary completionActual
Jun 21, 2021
CompletionActual
Jun 21, 2021
Last update
Jul 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04683185
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Dec 24, 2020
Start date
Dec 28, 2020
Primary completion
Jun 21, 2021
Completion
Jun 21, 2021
Last update
Jul 20, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: E6742

Start the discussion